

**REF**

**BIO85STBC**



**ARGUTUS MEDICAL**

# **Human Urine Stabilizing Buffer (Custom Fill)**

**Instructions for Use**

**For Research Use Only  
Not for use in Diagnostic Procedures**

## **INTENDED USE**

The Argutus Medical human urine stabilization buffer is a solution designed to preserve urinary proteins. It is recommended that human urine is diluted in the urine stabilization buffer prior to storage. Human urine must be diluted with stabilization buffer if being assayed with Argutus Medical Nephkit Alpha GST or Pi-GST EIAs.

## **COMPONENTS**

1. Human Urine Stabilizing Buffer  
Contains Thiomersal and sodium azide (1mL).  
READY TO USE

## **STABILITY AND STORAGE**

Urine Stabilising Buffer should be stored at 2-8°C and is stable as supplied until the expiry date shown.

## **PRECAUTIONS**

### **SAFETY**

- The Urine Stabilizing buffer contains Thiomersal, which may be toxic if ingested.
- The Urine Stabilizing buffer contains sodium azide, which may form potentially explosive metal azides with lead and copper plumbing. For disposal, reagents should be flushed with large volumes of water to prevent azide build up.
- Wear protective clothing, disposable latex gloves and eye protection while handling specimens. Wash hands thoroughly when finished.
- Do not pipette materials by the mouth and never eat or drink at the laboratory workbench.

### **PROCEDURAL**


- Do not use past the expiry date.
- Deviation from the protocol provided may cause erroneous results.
- Care must be taken not to contaminate the component and always use fresh pipette tips for each sample and component.
- Avoid leaving reagent in direct sunlight and/or above 2-8°C for extended periods.

## **SAMPLE COLLECTION**

As soon as possible after sample collection, add 4mL of Human Urine into the collection tube provided. The tube already contains 1mL of Argutus Medical Stabilising Buffer. The end volume should be 5mL.


### **Step 1**

- ④ Remove collection tube cap and ensure that there is 1mL of stabilizing buffer already in place.



### **Step 2**

- ④ Carefully decant human urine up to the 5mL mark.



## **SAMPLE HANDLING AND STORAGE**

Do not store samples without the addition of Urine Stabilizing Buffer. Urine Stabilising Buffer should ideally be added within 12 hours of sample collection. It is recommended that samples are assayed as soon as possible after collection. However, after the addition of Urine Stabilising Buffer, samples can be stored 2-8°C for one week or at -20°C for up to 28 days or -70°C for one year.

Repeated freeze thawing should be avoided. In the absence of Urine Stabilising Buffer, freezing can reduce GST levels in urine by up to 70% as measured by EIA. This decline in urinary GST is most likely due to denaturation during the freeze-thaw cycle.

## **OTHER ARGUTUS MEDICAL ASSAYS**

### **Pancreatic Injury Testing Service**

<b>Catalogue No</b>	<b>Product Name</b>	<b>Description</b>
<b>TEST BBU</b>	Trypsinogen Activation Peptide (TAP) EIA	TAP in human and mammalian urine and tissue

### **Animal Organ Damage Biomarkers**

<b>Catalogue No</b>	<b>Product Name</b>	<b>Description</b>
<b>BIO64RT</b>	Rat Alpha GST EIA	$\alpha$ GST in rat serum, urine and tissue culture
<b>BIO76YB1</b>	Rat Yb1 GST EIA	GSTYb1 ( $\mu$ GST) in rat urine
<b>BIO89RPA1</b>	RPA-1 EIA	Renal papillary antigen 1 in rat urine
<b>BIO87CD</b>	RPA-1 Antibody	Antibody to rat collecting duct
<b>BIO88LH</b>	RPA-2 Antibody	Antibody to rat loop of henle

### **Human Organ Damage Biomarkers**

<b>Catalogue No</b>	<b>Product Name</b>	<b>Description</b>
<b>BIO60HEPA</b>	HEPKIT® Alpha GST EIA	$\alpha$ GST in human serum and plasma
<b>BIO60HEPAS</b>	High Sensitivity Alpha GST EIA	$\alpha$ GST in human serum and plasma
<b>BIO66NEPHA</b>	Alpha GST EIA	$\alpha$ GST in human urine and plasma
<b>BIO85</b>	PI GST EIA	$\pi$ GST in human urine and plasma
<b>BIO83</b>	Urinary Collagen IV EIA	Collagen IV in human urine
<b>BIO82</b>	Serum Collagen IV EIA	Collagen IV in human serum
<b>BIO81DNA</b>	OxyDNA Test	Fluorescence method for the detection of oxidative DNA damage in cell suspensions



**ARGUTUS MEDICAL**

**Argutus Medical Ltd.**

**Unit 9 Trinity Technology & Enterprise Campus,**

**Pearse Street,**

**Dublin 2,**

**Ireland**

**Tel: +353 1 670 8576**

**Fax: +353 1 670 8575**

**[info@argutusmed.com](mailto:info@argutusmed.com)**

**<http://www.argutusmed.com>**

Document Code: STBC-457-02

03/09